We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$303M
Cap. Flow %
-7.88%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$487M
2
BPMC
Blueprint Medicines
BPMC
+$13.9M
3
ONC
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 45.68%
2 Consumer Discretionary 28.3%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$1.07B 27.75%
14,818,300
-6,000,000
-29% -$487M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$643M 16.72%
60,240,864
– –
GS icon
3
CALL
Goldman Sachs
GS
$304B
$235M 6.13%
1,050,000
+750,000
+250% +$174M
BAC icon
4
CALL
Bank of America
BAC
$448B
$133M 3.45%
4,500,000
-1,850,000
-29% -$56.3M
ONC
5
BeOne Medicines Ltd
ONC
$40.3B
$103M 2.69%
600,000
-75,000
-11% -$12.6M
GM icon
6
CALL
General Motors
GM
$75.8B
$101M 2.63%
3,000,000
+1,500,000
+100% +$55.3M
MS icon
7
CALL
Morgan Stanley
MS
$343B
$93.1M 2.42%
2,000,000
+500,000
+33% +$24.4M
WFC icon
8
CALL
Wells Fargo
WFC
$266B
$78.8M 2.05%
1,500,000
+500,000
+50% +$28.5M
RUBY
9
DELISTED
Rubius Therapeutics, Inc
RUBY
$69.8M 1.82%
+2,908,791
New +$66.5M
CELG
10
CALL
DELISTED
Celgene Corp
CELG
$67.1M 1.75%
750,000
-1,250,000
-63% -$110M
SRRK icon
11
Scholar Rock
SRRK
$6.46B
$61.7M 1.61%
2,396,040
– –
XLRN
12
DELISTED
Acceleron Pharma
XLRN
$57.2M 1.49%
1,000,000
– –
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$30.4B
$52.5M 1.37%
600,000
-50,000
-8% -$5.03M
NKTR icon
14
Nektar Therapeutics
NKTR
$2.57B
$48.8M 1.27%
53,333
-6,667
-11% -$5.69M
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$48.4M 1.26%
4,000,000
+1,100,000
+38% +$15.4M
BMY icon
16
CALL
Bristol-Myers Squibb
BMY
$132B
$46.6M 1.21%
750,000
-500,000
-40% -$29.7M
ATRA icon
17
Atara Biotherapeutics
ATRA
$76.7M
$41.4M 1.08%
40,000
– –
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$39M 1.02%
500,000
-200,000
-29% -$13.9M
FATE icon
19
Fate Therapeutics
FATE
$294M
$35.7M 0.93%
2,190,000
+490,000
+29% +$5.79M
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$31.2M 0.81%
800,000
– –
ANAB icon
21
AnaptysBio
ANAB
$1.66B
$29.9M 0.78%
300,000
+100,000
+50% +$8.3M
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
$28.9M 0.75%
1,900,000
-100,000
-5% -$1.53M
BLUE
23
DELISTED
bluebird bio
BLUE
$25.6M 0.66%
13,510
+386
+3% +$797K
PRQR icon
24
ProQR Therapeutics
PRQR
$261M
$25.2M 0.65%
1,300,000
-200,000
-13% -$2.13M
AGIO icon
25
Agios Pharmaceuticals
AGIO
$2B
$23.1M 0.6%
300,000
-50,000
-14% -$4.02M
1
2 3 4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $303M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.